A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough
Status:
Not yet recruiting
Trial end date:
2024-03-30
Target enrollment:
Participant gender:
Summary
This is a phase II study that will investigate the efficacy, safety and tolerability of
HRS-2261 in subjects with refractory chronic cough using a double blind, placebo controlled,
randomized study design.